Nektar Therapeutics Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Nektar Therapeutics filed its Q1 2024 10-Q, detailing financial performance, ongoing agreements, and restructuring efforts.</b>

AI Summary

NEKTAR THERAPEUTICS (NKTR) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Nektar Therapeutics filed a 10-Q report for the period ending March 31, 2024. The filing includes financial data such as accounts receivable, research and development expenses, and general and administrative expenses for Q1 2024. It references agreements including the Purchase and Sale Agreement 2020 and the Share Purchase Agreement with Bristol Myers Squibb Company from 2018. The report details restructuring plans, including employee severance and contract termination costs from 2022. Financial statement components like Additional Paid-In Capital and Accumulated Other Comprehensive Income are reported as of March 31, 2024, and prior periods.

Why It Matters

For investors and stakeholders tracking NEKTAR THERAPEUTICS, this filing contains several important signals. The 10-Q filing provides a snapshot of Nektar's financial health and operational activities for the first quarter of 2024, crucial for investors assessing current performance. Details on restructuring plans and specific agreements offer insight into the company's strategic adjustments and past partnerships, which can impact future revenue and expenses.

Risk Assessment

Risk Level: medium — NEKTAR THERAPEUTICS shows moderate risk based on this filing. The company's financial disclosures in this 10-Q, while standard, are part of a broader context of the biopharmaceutical industry which is subject to significant regulatory and market risks, and Nektar specifically has faced challenges in drug development and commercialization.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-Q to understand Nektar's current financial position and future outlook.

Key Numbers

• 2024-03-31 — Period End Date (Conformed Period of Report)
• 2024-05-10 — Filing Date (Filed as of date)
• 2024-01-01 to 2024-03-31 — Q1 2024 Period (Research and Development Expense reporting period)
• 2023-03-31 — Prior Period Balance Sheet Date (Sublease Property Plant and Equipment reporting date)

Key Players & Entities

• NEKTAR THERAPEUTICS (company) — Filer name
• Bristol Myers Squibb Company (company) — Mentioned in relation to Share Purchase Agreement
• 2024-03-31 (date) — Period of report
• 2024-05-10 (date) — Filing date

FAQ

Risk Factors

• Financial Condition [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional financing and achieve profitability.
• Regulatory Risks [high — regulatory]: The development and commercialization of pharmaceutical products are subject to extensive regulatory review and approval processes by agencies like the FDA.
• Market Competition [medium — market]: The company faces intense competition from other biotechnology and pharmaceutical companies, which could impact its ability to market and sell its products.

Key Dates

• 2024-03-31: Quarterly Report End Date — Marks the end of the reporting period for the 10-Q filing.
• 2024-05-10: 10-Q Filing Date — Date the report was officially filed with the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC), that provides a continuing disclosure by public companies. (Provides a regular update on the company's financial performance and condition.)

Accumulated Other Comprehensive Income

Represents unrealized gains and losses that are not included in net income on the income statement. (Indicates potential future impacts on equity that have not yet been recognized in net income.)

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR NASDAQ Capital Marke

Filing Documents

• nktr-20240331.htm (10-Q) — 1452KB
• nktr-ex10_16.htm (EX-10.1(6)) — 45KB
• nktr-ex31_1.htm (EX-31.1) — 13KB
• nktr-ex31_2.htm (EX-31.2) — 13KB
• nktr-ex32_1.htm (EX-32.1) — 9KB
• 0000950170-24-057312.txt (&nbsp;) — 6163KB
• nktr-20240331.xsd (EX-101.SCH) — 1019KB
• nktr-20240331_htm.xml (XML) — 904KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements — Unaudited: 6 Condensed Consolidated Balance Sheets — March 31, 2024 and December 31, 2023 6 Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 7 Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 8 Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023 9 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32

: OTHER INFORMATION

PART II: OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55 Item 3. Defaults Upon Senior Securities 55 Item 4. Mine Safety Disclosures 55 Item 5. Other Information 55 Item 6. Exhibits 56

Signatures

Signatures 58 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of any collaboration arrangements, commercialization activities and product sales levels and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as "believe," "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "continue," or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reaso

: FINANCI AL INFORMATION

PART I: FINANCI AL INFORMATION

Condensed Consolidated Financial Statements—Unaudited

Item 1. Condensed Consolidated Financial Statements—Unaudited: NEKTAR THERAPEUTICS CONDENSED CONSOLID ATED BALANCE SHEETS (In thousands, except par value) (Unaudited) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 48,642 $ 35,277 Short-term investments 240,596 268,339 Accounts receivable 3,617 1,205 Inventory, net 16,238 16,101 Other current assets 10,743 9,779 Total current assets 319,836 330,701 Long-term investments 36,778 25,825 Property, plant and equipment, net 17,475 18,856 Operating lease right-of-use assets 17,267 18,007 Other assets 4,656 4,644 Total assets $ 396,012 $ 398,033 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 8,757 $ 9,848 Accrued expenses 24,281 22,162 Operating lease liabilities, current portion 19,368 19,259 Total current liabilities 52,406 51,269 Operating lease liabilities, less current portion 94,710 98,517 Liabilities related to the sales of future royalties, net 117,857 112,625 Other long-term liabilities 4,334 4,635 Total liabilities 269,307 267,046 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2024 or December 31, 2023, respectively — — Common stock, $ 0.0001 par value; 300,000 shares authorized; 191,909 shares and 191,384 shares issued at March 31, 2024 and December 31, 2023, respectively; 183,624 shares and 191,384 shares outstanding at March 31, 2024 and December 31, 2023, respectively; 19 19 Capital in excess of par value 3,644,140 3,608,137 Treasury stock, at cost; 8,285 shares as of March 31, 2024 and no ne as of December 31, 2023, respectively ( 3,000 ) — Accumulated other comprehensive income (loss) ( 403 ) 80 Accumulated deficit ( 3,514,051 ) ( 3,477,249

View Full Filing

View this 10-Q filing on SEC EDGAR